{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:40:07Z","timestamp":1750030807792,"version":"3.41.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.wneu.2017.02.104","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T19:37:21Z","timestamp":1488483441000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3471-0575","authenticated-orcid":false,"given":"Florian","family":"Gessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Zappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Konczalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Bernstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Therese","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Senft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.wneu.2017.02.104_bib1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib3","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.18632\/oncotarget.3440","article-title":"Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2017.02.104_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ane.12481","article-title":"Prognostic factors for glioblastoma patients\u2014a clinical population-based study","volume":"133","author":"Fekete","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.wneu.2017.02.104_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00401-014-1353-4","article-title":"Oligoastrocytomas: throwing the baby out with the bathwater?","volume":"129","author":"Wilcox","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00401-014-1359-y","article-title":"Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true \u201coligoastrocytoma\u201d?","volume":"129","author":"Huse","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2353\/jmoldx.2010.090228","article-title":"Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies","volume":"12","author":"Horbinski","year":"2010","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.wneu.2017.02.104_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2017.02.104_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1215\/15228517-2009-025","article-title":"IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas","volume":"11","author":"Ichimura","year":"2009","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.wneu.2017.02.104_bib11","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2017.02.104_bib12","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.wneu.2017.02.104_bib13","first-page":"1176","article-title":"Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review","volume":"118","author":"Hodges","year":"2013","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2017.02.104_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2017.02.104_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010","journal-title":"Brain Pathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.wneu.2017.02.104_bib17","unstructured":"Agency EM, Weller M. Temozolomide, INN-temozolomide, Interdisziplin\u00e4re S 2 \u2013 Leitlinie f\u00fcr\u00a0die\u00a0Diagnostik und Therapie der Gliome des Erwachsenenalters. Available at: http:\/\/www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/000229\/WC500035621.pdf http:\/\/www.krebsgesellschaft.de\/download\/ebm-leitlinie_gliome.pdf. Accessed February 10, 2015."},{"key":"10.1016\/j.wneu.2017.02.104_bib18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2017.02.104_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis","volume":"6","author":"Lamborn","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2017.02.104_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2017.02.104_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2017.02.104_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2157-2","article-title":"Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma","volume":"129","author":"Mandel","year":"2016","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","article-title":"Bevacizumab Plus Irinotecan Versus Temozolomide in newly diagnosed o6-methylguanine-dna methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial","volume":"34","author":"Herrlinger","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib27","first-page":"3","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2017.02.104_bib28","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/annonc\/mdt388","article-title":"Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy","volume":"24","author":"Kreth","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-014-1397-2","article-title":"Benefit of tumor resection for recurrent glioblastoma","volume":"117","author":"Quick","year":"2014","journal-title":"J\u00a0Neuro-oncol"},{"key":"10.1016\/j.wneu.2017.02.104_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.anndiagpath.2011.08.010","article-title":"Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults","volume":"16","author":"Olar","year":"2012","journal-title":"Ann Diagn Pathol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017302772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017302772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:27:57Z","timestamp":1750030077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875017302772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"alternative-id":["S1878875017302772"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2017.02.104","relation":{},"ISSN":["1878-8750"],"issn-type":[{"type":"print","value":"1878-8750"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2017.02.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}